<DOC>
	<DOC>NCT00246636</DOC>
	<brief_summary>The purpose of OM5/LOV111859 was to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) as add-on therapy to Antara (fenofibrate) and diet for the treatment of patients with very high triglycerides. The purpose of both OM5X/LOV111860 was to assess the continued efficacy and safety of adjunctive Lovaza (omega-3-acid ethyl esters) therapy in hypertriglyceridemic subjects treated with fenofibrate in lowering serum triglyceride (TG) levels.</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension</brief_title>
	<detailed_description>Three studies comprise this OM5 Program - Study OM5 / LOV111859 (double-blind study) and OM5X / LOV111860 (1st open-label extension) are part of this listing on ClinicalTrials.gov - NCT00246636. - Study OM5XX / LOV111821 (2nd open-label extension) is listed as a separate listing on ClinicalTrials.gov - NCT00891293</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>For OM5/LOV111858 Men and women ages 1879 years, inclusive Triglyceride levels between 500 mg/dL and &lt;1300 mg/dL Body mass index between 25 and 43 kg/m2 Willingness to follow a lowsaturated fat diet during the study period and maintain current physical activity level Normally active and in good health on the basis of medical history, brief physical examination, electrocardiogram, and routine laboratory tests Provide written informed consent and authorization for protected health information disclosure Sensitivity to fibrate drugs or omega3 fatty acids Lipoprotein lipase impairment or apo C2 deficiency or Type III hyperlipidemia History of pancreatitis Recent history of certain kidney, liver, lung, or gastrointestinal disease or cancer (except nonmelanoma skin cancer) Poorly controlled diabetes mellitus Type 1 diabetes Pregnant or lactating females. Women of childbearing potential who are not using a medically approved method of contraception. Use of certain types of hormones, anticonvulsant drugs, immunologic drugs, antibiotic, antifungal and antiviral drugs, and cardiac drugs Use of isotretinoin (Accutane) Use of warfarin (Coumadin) For OM5X/LOV111859 Subjects were included in the study if they met the following criteria: 1. Satisfied all inclusion and exclusion criteria prior to and throughout the previous OM5 study or had a corresponding approved protocol deviation 2. Successfully completed the previous OM5 doubleblind study to Week 8 3. Provided written informed consent on or before the Week 8 clinic visit of the OM5 doubleblind study (i.e., Visit 1X of the OM5X extension study)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Very high triglycerides</keyword>
	<keyword>omega-3-acid ethyl esters</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>Lovaza</keyword>
</DOC>